WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Shamil Al-Jebori*

ABSTRACT

A brief mono- antifungal regimen is no longer adequate to successfully clear fungus and stop it rising again. With the exponential rise in refractory dermatophytoses, this demand keeps growing. The study's objective was to assess the efficacy of long course oral itraconazole monotherapy in treating chronic dermatophytosis. This is an open-labeled trial performed on 85 patients with chronic dermatophytosis in different parts of the body between June 2023 to July 2024. For sixteen weeks, patients received 200mg of itraconazole daily. Response was assessed clinically using clinic outcome score. Results reveal the mild itch persist in 5 (0.07%) of patients and moderate itch in 1 (0.01%). Erythema had vanished completely in 76 (90.54%), mild in 5 (0.07%) and moderate in 2 (0.03%). only one patient shows active border. Extent of lesions dropped significantly from 2.25 ± 0.67%. to 0.01 ± 0.003%. The overall clinical score dramatically decreases from 24.80±6.27 to 0.04±0.20. The clinical outcome score was classified as cure in 68 (91.89%), partial cure in 6 (0.08%), and none was considered failure. In conclusion, itraconazole in a dose of 200mg daily for as long as 16 weeks is an effective regimen in eradicating dermatophytosis in different part of the body.